Positive Clinical Experience
Peer-reviewed journal articles provide clinical evidence credentialing NeuroGlove technology
NeuroGlove Brings Hope to Patients by Offering a Non-Invasive, Non-Drug Therapy
Patient improvement certified by pMRI showing increase in cerebral blood flow when device was activated. All PTSD, Anxiety, and Depression subjects demonstrated statistically significant dramatic improvement.
PTSD
All PTSD subjects demonstrated statistically significant improvement
In a 4-week trial involving 6 patients diagnosed with PTSD, PSS showed promising results. All participants experienced symptom reduction within one week, with sustained improvement over the course of the trial. Surveys assessing well-being and PTSD severity demonstrated significant patient improvement. A cumulative link mixed model analysis revealed a 38.2-fold higher likelihood of improved scores with the use of NeuroGlove. No adverse events were reported, and all patients expressed satisfaction, indicating potential for PSS therapy in managing PTSD symptoms.
Anxiety
All anxiety subjects demonstrated statistically significant improvement
Anxiety poses substantial societal challenges, impacting quality of life and incurring significant costs. This clinical trial explores Peripheral Somatosensory Stimulation (PSS) therapy as a non-invasive approach to alleviate symptoms. The trial involved ten participants diagnosed with depression and anxiety who used the NeuroGlove device at home for one hour daily over four weeks. Results showed a remarkable improvement in symptoms within one week, with sustained benefits. Surveys measuring patient satisfaction, anxiety, and depression symptoms demonstrated statistically significant improvements. Compliance exceeded 92%, and no adverse events were reported. Patients expressed enjoyment and a desire to keep the device. The promising outcomes suggest further investigation into PSS therapy for anxiety treatment is warranted.
Depression
All depression subjects demonstrated statistically significant improvement
Depression poses substantial societal challenges, impacting quality of life and incurring significant costs. This clinical trial explores Peripheral Somatosensory Stimulation (PSS) therapy as a non-invasive approach to alleviate symptoms. The trial involved ten participants diagnosed with depression who used the NeuroGlove device at home for one hour daily over four weeks. Results showed a remarkable improvement in symptoms within one week, with sustained benefits. Surveys measuring patient satisfaction, anxiety, and depression symptoms demonstrated statistically significant improvements. Compliance exceeded 92%, and no adverse events were reported. Patients expressed enjoyment and a desire to keep the device. The promising outcomes suggest further investigation into PSS therapy for depression treatment is warranted.
Traumatic Brain Injury
Traumatic Brain Injury subjects improved cognitive, behavioral, and physical functions
The study, conducted on six patients diagnosed with active Post-Traumatic Stress Disorder (PTSD), three of whom had a history of TBI, utilized the NeuroGlove device for non-invasive PSS therapy. The patients underwent one hour of daily therapy for four weeks. Results, assessed through the Veterans Affairs TBI Evaluation, indicated overall improvement in mental health symptoms, particularly in anxiety, depression, and general well-being. Despite the study's limited sample size, the positive outcomes suggest that PSS may have potential benefits for individuals with TBI, encouraging further investigation into its efficacy as a treatment method for this patient population.
Insomnia
All insomnia subjects demonstrated statistically significant improvement
In a 4-week trial involving 12 patients diagnosed with Insomnia, PSS showed promising results. All patients had overall improvements by week 4, with statistically significant improvements for every individual. Results from our study suggest most patients having moderately severe insomnia at baseline compared to typically no symptoms or minimal symptoms by the end of the study.
Peer reviewed published article pending, please check back to review complete study results.
